Cargando…
CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment
Despite the development of targeted therapies and novel inhibitors, cancer remains an undefeated disease. Resistance mechanisms arise quickly and alternative treatment options are urgently required, which may be partially met by drug combinations. Protein kinases as signaling switchboards are freque...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760252/ https://www.ncbi.nlm.nih.gov/pubmed/33255177 http://dx.doi.org/10.3390/ph13120418 |
_version_ | 1783627289161891840 |
---|---|
author | Scheiblecker, Lisa Kollmann, Karoline Sexl, Veronika |
author_facet | Scheiblecker, Lisa Kollmann, Karoline Sexl, Veronika |
author_sort | Scheiblecker, Lisa |
collection | PubMed |
description | Despite the development of targeted therapies and novel inhibitors, cancer remains an undefeated disease. Resistance mechanisms arise quickly and alternative treatment options are urgently required, which may be partially met by drug combinations. Protein kinases as signaling switchboards are frequently deregulated in cancer and signify vulnerable nodes and potential therapeutic targets. We here focus on the cell cycle kinase CDK6 and on the MAPK pathway and on their interplay. We also provide an overview on clinical studies examining the effects of combinational treatments currently explored for several cancer types. |
format | Online Article Text |
id | pubmed-7760252 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77602522020-12-26 CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment Scheiblecker, Lisa Kollmann, Karoline Sexl, Veronika Pharmaceuticals (Basel) Review Despite the development of targeted therapies and novel inhibitors, cancer remains an undefeated disease. Resistance mechanisms arise quickly and alternative treatment options are urgently required, which may be partially met by drug combinations. Protein kinases as signaling switchboards are frequently deregulated in cancer and signify vulnerable nodes and potential therapeutic targets. We here focus on the cell cycle kinase CDK6 and on the MAPK pathway and on their interplay. We also provide an overview on clinical studies examining the effects of combinational treatments currently explored for several cancer types. MDPI 2020-11-24 /pmc/articles/PMC7760252/ /pubmed/33255177 http://dx.doi.org/10.3390/ph13120418 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Scheiblecker, Lisa Kollmann, Karoline Sexl, Veronika CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment |
title | CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment |
title_full | CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment |
title_fullStr | CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment |
title_full_unstemmed | CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment |
title_short | CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment |
title_sort | cdk4/6 and mapk—crosstalk as opportunity for cancer treatment |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760252/ https://www.ncbi.nlm.nih.gov/pubmed/33255177 http://dx.doi.org/10.3390/ph13120418 |
work_keys_str_mv | AT scheibleckerlisa cdk46andmapkcrosstalkasopportunityforcancertreatment AT kollmannkaroline cdk46andmapkcrosstalkasopportunityforcancertreatment AT sexlveronika cdk46andmapkcrosstalkasopportunityforcancertreatment |